Brief: FDA grants orphan drug designation to Nuvilex pancreatic cancer treatment
22/12/2014 13:30
Dec 22 (Reuters) - Nuvilex Inc NVLX.PK : * FDA grants orphan drug designation to Nuvilex for pancreatic cancer treatment * Says nuvilex's clinical trial is planned to commence in 2015 * Source text for Eikon ID:nGNXVCJHHa * Further company coverage NVLX.PK ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Pharmacyte Biotech
See all newsBrief: Pharmacyte Biotech Inc - Increases Stake In Tnf Pharmaceuticals By $3 Million
Brief: PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
Brief: Pharmacyte Biotech Acquires $5 Million Stake In Emerging Women’S Health Innovator Femasys
Brief: Femasys Inc. Secures Additional Financing With Strategic Investment From Investors Led By Pharmacyte Biotech
Brief: Pharmacyte Biotech Announces Final Results Of Tender Offer